Atjaunināt sīkdatņu piekrišanu

E-grāmata: Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Roadmaps for the Best Practices

(Vice President, Biomarkers and Companion Diagnostics, Taiho Oncology, NJ, USA)
  • Formāts: EPUB+DRM
  • Izdošanas datums: 08-Jun-2019
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780128161227
Citas grāmatas par šo tēmu:
  • Formāts - EPUB+DRM
  • Cena: 151,21 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Biomarkers, Diagnostics and Precision Medicine in the Drug Industry: Critical Challenges, Limitations and Roadmaps for the Best PracticesPalielināt
  • Formāts: EPUB+DRM
  • Izdošanas datums: 08-Jun-2019
  • Izdevniecība: Academic Press Inc
  • Valoda: eng
  • ISBN-13: 9780128161227
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

Biomarkers, Diagnostics, and Precision Medicine in the Drug Industry: Critical Challenges, limitations and Road Maps for the Best Practices examines the challenges and limitations in biomarkers and laboratory tests, offering advice on best practices to ensure the proper application of biomarkers and bridging the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, including standard-of-care approved assays and for-investigational-use and for-research-use-only assays. The book also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples.

Users will find this to be an ideal resource that is perfect for drug developers, IVD providers, healthcare givers, academics and researchers who need best practices to help them increase their probability of success.

  • Provides the unique insights of an expert with extensive experience in diagnostics, clinical laboratories, and drug discovery and development
  • Addresses the challenges of drug development and precision medicine and suggests how to eliminate or mitigate these challenges through better utilization of biomarkers
  • Features case studies and real-life examples from different classes of biomarkers on different platforms for different therapeutic areas

1. Pharmaceutical crisis2. Applications of biomarkers for different purposes in drug development
3. Pharmacogenetics of therapeutics4. Precision medicine and companion diagnostics in drug development5. Essential attributes of an acceptable in-vitro diagnostic test6. Fundamentals of Assay Development and Validation7. Essentials of Laboratory Quality Management8. Biological variables and their potential impact on biomarkers and precision medicine initiative9. Pre-analytical Variables and their potential impact on biomarkers and precision medicine initiative10. Analytical Discrepancies and their potential impact on biomarkers and precision medicine initiative11. Road Map to Best Practices

Dr Abdel B. Halim is an internationally-recognized key opinion leader with 25+ years of experience in different aspects of biomarkers, precision medicine and IVD; from strategic planning to actualization. He is the Vice president of Biomarkers and Companion Diagnostics at Taiho Oncology (Otsuka holding). Before Taiho, Dr. Halim held multiple leadership positions in the pharmaceutical and diagnostic industries. He oversaw the development and validation of assays for several hundreds of biomarkers on different platforms and their applications in 150+ PI-PIII clinical trials and patient managements. Abdel has led 8 CDx programs and has track records for 5 FDA high complexity IVD approvals and 2 drug approvals. Abdel has served on 20+ governmental and public expert panels and advisory boards in the US, Canada and EU. Dr. Halim has served on 25+ committees to establish guidelines to promote quality in clinical laboratory and diagnostic industries and authored about 15 guidelines. Abdel has 70+ peer-reviewed publications, two book chapters and 100+ presentations including 40+ invited and keynote speeches in national and international meetings.
Biežāk uzdotie jautājumi par e-grāmatām Biežāk uzdotie jautājumi par e-grāmatām
Permanent link: https://www.kriso.lv/db/97801281612276e.html
Keywords: